Overview

Obesity is a global public problem and increases the risk of cardiovascular disease, among others. Combining pharmacological treatments with lifestyle changes plays an important role in reversing the burden of obesity. Drug metabolism and pharmacokinetic (DMPK) studies are mandatory in preclinical studies of anti-obesity drugs. It evaluates a wide range of drug properties including bioavailability, the extent and rate of absorption, and efficacy of the active ingredient of the drug. Protheragen devotes significant effort to the development of innovative anti-obesity therapies and provides a customized DMPK studies service for a wide range of anti-obesity drugs in preclinical studies. Our researchers provide critical analytical support for anti-obesity drug discovery and development using advanced methods and technologies.

Collaborate with Us for Your Anti-Obesity Drug Development and DMPK Studies

Our DMPK research services are designed to help rapidly evaluate the drug properties and safety of potential anti-obesity drugs. Using our DMPK research platform, we select the most effective anti-obesity drugs and optimize drug discovery and preclinical studies. Specific services include the following:

Anti-Obesity Drug Development

We target a variety of targets to develop anti-obesity drugs, including various receptors, enzymes, and so on. The anti-obesity effect is exerted by targeting different mechanisms of multiple factors and different pathways leading to positive energy balance. In addition, a variety of natural products also have certain anti-obesity activity and have potential in the treatment of obesity. We also screen various natural products with therapeutic potential or modify natural products and study their Pharmacodynamics, PK, and Safety.

DMPK Study

Based on a well-established drug discovery platform, we provide DMPK study services for anti-obesity drugs. We have a variety of advanced technologies, such as liquid chromatography with tandem mass spectrometry (LC-MS-MS), high-performance liquid chromatography (HPLC), etc., for comprehensive analysis of metabolites, etc.

• Construction of Obesity Model

  Based on our well-established research platform and excellent in vivo expertise, we have a wide range of Animal Models (Mice, Rats, Rabbits, Dogs, etc.) and tissue types to conduct DMPK studies for anti-obesity drugs. In addition to this, we have constructed various in vitro Cell Models to study the pharmacokinetic profile of various anti-obesity drugs. We maximize client satisfaction through a comprehensive range of obesity models and experiments to provide valuable information for anti-obesity drug development.

• In vitro DMPK studies

  Combining data from in vitro DMPK studies with in vivo experimental data allows for more accurate extrapolation of PK characteristics of anti-obesity drugs. We used various cellular models to analyze the metabolic profiles, bioavailability, interactions of anti-obesity drugs, etc. Advanced and comprehensive assay technologies enable us to obtain accurate and reliable data.

• In vivo DMPK studies

  Administration: We use various routes of administration (intravenous, oral, intraperitoneal, subcutaneous, intramuscular) to administer single, multiple, or combined doses, and analyze individual indicators. Different routes of administration affect drug absorption, bioavailability, and suitability for specific experiments. We are familiar with the various routes of administration and conduct studies to determine the optimal mode of administration.

  Drug evaluation: After administration, we perform various analyses to study the DMPK and safety of anti-obesity drugs.

  • Bioavailability
  • Drug distribution
  • Quantitative analyses of drugs and metabolites
  • Drug-drug interactions
  • Metabolite identification
  • Quantitative radioautography studies

  • Maximal tolerance dose (MTD)
  • Gene expression profiling
  • Excretion determination
  • Metabolite safety evaluation
  • Others

Workflow

We complete all studies for anti-obesity drug development, MTD analysis, DMPK studies, and dosing regimen analysis.

Applications

• Dosing analysis: DMPK studies of anti-obesity drugs allow analysis of the effects of different routes of administration and dosages on the efficacy of obesity treatments, thus providing valuable information for the development of more effective dosing strategies.
• Development of anti-obesity therapies: The study of DMPK of potential anti-obesity drugs helps to promote the development of reliable anti-obesity therapies.
• Drug interaction analysis: In the study of anti-obesity therapies that use multiple drugs simultaneously, DMPK studies are used to analyze the interactions between these drugs.

Advantages

• Our anti-obesity drug DMPK research team has solid technical skills, extremely high scientific standards, and extensive experience in drug discovery and development.
• Our hands-on scientific staff strives to understand the uniqueness of each project, and efficiently design and complete each DMPK study.
• Our scientific team also provides reliable expertise or advice to clients on anti-obesity study design, experiment conduct, and data interpretation.

Other Personalized Services

Publication Data

Frequently Asked Questions

How is the timing of blood collection determined for the anti-obesity drug DMPK study?

• For single-dose administration, blood is taken at steady-state blood concentrations.
• For multi-dose administration, blood is collected before the next dose after a steady state has been reached.
• When over- or under-dosing is suspected, blood is collected at the steady-state peak or trough concentration.

What are the differences between the different routes of administration?

Common routes of administration include oral, intravenous, subcutaneous, etc., all of which have different rates of absorption. The PK and convenience of a drug affect the effectiveness of different routes of administration.

• Intravenous drug administration: After intravenous injection, the drug is not digested and absorbed, and directly enters the blood circulation, which has a rapid onset of action, is not affected by various factors, and plays a systemic or local therapeutic effect. Some drugs are not easily absorbed by the gastrointestinal tract or for other reasons, can not be administered by the oral route, but also need to use the injection of drugs.
• Oral administration: It is the most frequently used, convenient, safe, and economical method of drug delivery. However, it is important to note that some drugs, due to their physicochemical properties, may lead to a reduction in the amount of drug entering the body and a decrease in efficacy.
• Subcutaneous: The subcutaneous route is widely used for administering different types of drugs due to its rapid onset of action and high bioavailability. The subcutaneous route is used when the size of the drug molecule is too large to be absorbed efficiently in the intestinal tract when better bioavailability or a faster rate of absorption is required.

Protheragen offers a flexible and reliable DMPK study service for anti-obesity drugs to help you quickly assess the properties and safety of the anti-obesity drug under study. The fast turnaround of our projects will help you make timely and critical decisions in anti-obesity drug development. Please feel free to contact us and tell us about your detailed research needs.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

• ADME Study of Anti-Obesity Drugs